Oragenics, Inc. Announces Pricing of Public Offering
25 Juni 2024 - 2:30PM
Oragenics, Inc. (NYSE American: OGEN), a company focused on
developing unique, intranasal pharmaceuticals for the treatment of
neurological disorders, today announced that it has entered
into a placement agency agreement for the purchase and sale of
1,100,000 shares of its common stock (or pre-funded warrants in
lieu thereof) at an offering price of $1.00 per share. The closing
of the public offering is expected to occur on or about June 26,
2024, subject to the satisfaction of customary closing conditions.
The gross proceeds of the offering are
anticipated to be approximately $1,100,000 million before deducting
placement agent fees and other estimated offering expenses payable
by the Company. The Company intends to use the net proceeds from
the offering to fund the continued development of its ONP-002
product candidate and for general corporate purposes and working
capital.
Dawson James Securities, Inc. is acting as the
sole placement agent for the offering.
The offering is being made pursuant to a shelf
registration statement on Form S-3 (File No. 333-269225), including
a base prospectus, filed with the U.S. Securities and Exchange
Commission (the “SEC”) on January 13, 2023, and declared effective
on January 25, 2023. The offering will be made only by means of a
written prospectus. A preliminary prospectus supplement and
accompanying prospectus describing the terms of the offering has
been or will be filed with the SEC and will be available on its
website at www.sec.gov. Copies of the preliminary prospectus
supplement and the accompanying prospectus relating to the offering
may also be obtained from Dawson James Securities, Inc., 101 North
Federal Highway, Suite 600, Boca Raton, FL 33432, or by telephone
at (561) 391-5555, or by email at
investmentbanking@dawsonjames.com. Before investing in this
offering, interested parties should read in their entirety the
preliminary prospectus supplement and the accompanying prospectus
and the other documents that the Company has filed with the SEC
that are incorporated by reference in such preliminary prospectus
supplement and the accompanying prospectus, which provide more
information about the Company and such offering, which will provide
more information about Oragenics and the offering.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Oragenics
Oragenics is a development-stage biotechnology
company focused on nasal delivery of pharmaceutical medications in
neurology and fighting infectious diseases, including drug
candidates for treating mild traumatic brain injury (mTBI), also
known as concussion, and for treating Niemann Pick Disease Type C
(NPC), as well as proprietary powder formulation and an intranasal
delivery device. For more information, please
visit www.oragenics.com.
Forward-Looking Statements
This communication contains “forward-looking
statements” within the meaning of the safe harbor provisions of the
U.S. Private Securities Litigation Reform Act of 1995, including
with regard to the Company’s ability to regain compliance with the
NYSE American’s continued listing standards by October 18, 2025.
These forward-looking statements are based on management’s beliefs
and assumptions and information currently available. The words
"believe," "expect," "anticipate," "intend," "estimate," "project"
and similar expressions that do not relate solely to historical
matters identify forward-looking statements. Investors should be
cautious in relying on forward-looking statements because they are
subject to a variety of risks, uncertainties, and other factors
that could cause actual results to differ materially from those
expressed in any such forward-looking statements. These factors
include, but are not limited to those described in our Form 10-K
and other filings with the U.S. Securities and Exchange Commission.
All information set forth in this press release is as of the date
hereof. You should consider these factors in evaluating the
forward-looking statements included in this press release and not
place undue reliance on such statements. We do not assume any
obligation to publicly provide revisions or updates to any
forward-looking statements, whether as a result of new information,
future developments or otherwise, should circumstances change,
except as otherwise required by law.
Oragenics, Inc.Janet Huffman, Chief Financial
Officer813-286-7900jhuffman@oragenics.com
Oragenics (AMEX:OGEN)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Oragenics (AMEX:OGEN)
Historical Stock Chart
Von Sep 2023 bis Sep 2024